1. CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors. (October 2022) Authors: Wang, S.; Arribas, A.J.; Tarantelli, C.; Pradier, A.; Zucca, E.; Rossi, D.; Simonetta, F.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). (June 2017) Authors: Arribas, A.J.; Gaudio, E.; Rinaldi, A.; Cascione, L.; Tarantelli, C.; Kwee, I.; Stathis, A.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Cascione, L.; Civanelli, E.; Cannas, E.; Mensah, A.A.; Arribas, A.J.; Rinaldi, A.; Stathis, A.; Di Conza, G.; Niewola-Staszkowska, K.; Lahn, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models. (October 2020) Authors: Spriano, F.; Barreca, M.; Miguel-Gordo, M.; O'Brien, S.; Arribas, A.J.; Jennings, L.; Thomas, O.; Bertoni, F. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The antimetabolite KAT/3BP has in vitro and in vivo anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Civanelli, E.; Arribas, A.J.; Aresu, L.; Risi, G.; Kayali, O.; Stathis, A.; Ko, Y.H.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds. (October 2022) Authors: Spriano, F.; Arribas, A.J.; Tarantelli, C.; Sartori, G.; Gaudio, E.; Driessen, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗